Vaccine Research with Marc LaForce (NPF Vaccine Webinar Series)
12
National Press Foundation Vaccine Webinar Series VACCINE RESEARCH Dr. Marc LaForce November 29, 2011
-
date post
21-Oct-2014 -
Category
Health & Medicine
-
view
491 -
download
5
description
We discuss the costs associated with research and the difficulty of safe manufacturing. Why are vaccine facilities so difficult to establish? Why are some diseases ignored? What new vaccines are in the pipeline, and how does the threat of bio-terrorism affect the nation’s vaccine agenda? Special guest: Dr. Marc LaForce, Global Program Leader, Meningitis Vaccine Project, PATH
Transcript of Vaccine Research with Marc LaForce (NPF Vaccine Webinar Series)
National Press Foundation Vaccine Webinar Series
VACCINE RESEARCH
Dr. Marc LaForce November 29, 2011
Vaccine Research
A new meningitis vaccine for Africa
Vaccine Webinar Series
National Press Foundation November 29, 2011
Marc LaForce, PATH
3 3
The road to a new vaccine
4 4
Vaccine manufacturers Five Pharma firms (US/Eur)
• Profitable companies • Charge high prices for new vaccines • Concentrate on low-volume rich world markets
Emerging suppliers
• Traditionally sell older, less complex vaccines • High-volume and low-margin markets • Interest in developing more complex (higher
margin) vaccines
5 5
Problems for vaccines aimed at developing country problems
Development of new vaccines controlled by
Pharma and aimed at products with market potential
Very slow introduction of new products to developing countries
Hepatitis B vaccine HiB conjugate vaccine
6 6
Meningitis in Sub-Saharan Africa
• Over 90 percent of global meningococcal disease occurs in the African meningitis belt
• Attacks children, young adults and infants
• One third of meningitis cases die (10%) or are disabled (23%)
• One strain (Group A Nm) accounts for estimated 80% of all meningococcal cases.
• Epidemics occur every year
• Poorest countries in the world
• New vaccine cost is critical to sustainability
7 7
•The “intensive care unit” of Africa
•Individuals are treated where they fall
•Very few hospitals in this region; makeshift clinics are established when needs arise
Small clinic for meningitis patients
Presenter
Presentation Notes
Human terms Koudougou Health Center The hospital bed is the ground
8 8
Serum Institute of India Ltd. (SIIL)
Largest “emerging supplier” World’s largest producer of measles and DTP Two-thirds of the world’s immunized children are vaccinated by a vaccine
manufactured by SIIL
Partnered with the Meningitis Vaccine Project to develop an affordable
(< $US 0.50 per dose) vaccine designed specifically for Africa to protect against
meningococcal meningitis
9 9
2010 introduction of MenAfriVac™
20 million people in Burkina Faso (100%), Mali (50%), and Niger (50%) vaccinated
In 2011 in Burkina Faso: Lowest number of reported cases of
meningitis Not a single case of meningitis A in
individuals vaccinated with MenAfriVac™ Group immunity established with use of the
vaccine
10 10
National Press Foundation Vaccine Webinar Series
VACCINE RESEARCH
Q&A
Dr. Marc LaForce November 29, 2011
